Efficacy trial of pipobroman in essential thrombocythemia

A study of 24 patients

E. Brusamolino, A. Canevari, L. Salvaneschi, S. Merante, C. Bernasconi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.

Original languageEnglish
Pages (from-to)1339-1342
Number of pages4
JournalCancer Treatment Reports
Volume68
Issue number11
Publication statusPublished - 1984

Fingerprint

Pipobroman
Essential Thrombocythemia
Plateletpheresis
Thrombocytosis
Amenorrhea
Platelet Count
Leukemia
Survival Rate
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brusamolino, E., Canevari, A., Salvaneschi, L., Merante, S., & Bernasconi, C. (1984). Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients. Cancer Treatment Reports, 68(11), 1339-1342.

Efficacy trial of pipobroman in essential thrombocythemia : A study of 24 patients. / Brusamolino, E.; Canevari, A.; Salvaneschi, L.; Merante, S.; Bernasconi, C.

In: Cancer Treatment Reports, Vol. 68, No. 11, 1984, p. 1339-1342.

Research output: Contribution to journalArticle

Brusamolino, E, Canevari, A, Salvaneschi, L, Merante, S & Bernasconi, C 1984, 'Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients', Cancer Treatment Reports, vol. 68, no. 11, pp. 1339-1342.
Brusamolino E, Canevari A, Salvaneschi L, Merante S, Bernasconi C. Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients. Cancer Treatment Reports. 1984;68(11):1339-1342.
Brusamolino, E. ; Canevari, A. ; Salvaneschi, L. ; Merante, S. ; Bernasconi, C. / Efficacy trial of pipobroman in essential thrombocythemia : A study of 24 patients. In: Cancer Treatment Reports. 1984 ; Vol. 68, No. 11. pp. 1339-1342.
@article{6f7558f6d061445fb56694a55f225e3b,
title = "Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients",
abstract = "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92{\%} of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20{\%} of the cases; the 5-year overall and complication-free survival rates were 92{\%} and 75{\%}, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.",
author = "E. Brusamolino and A. Canevari and L. Salvaneschi and S. Merante and C. Bernasconi",
year = "1984",
language = "English",
volume = "68",
pages = "1339--1342",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "11",

}

TY - JOUR

T1 - Efficacy trial of pipobroman in essential thrombocythemia

T2 - A study of 24 patients

AU - Brusamolino, E.

AU - Canevari, A.

AU - Salvaneschi, L.

AU - Merante, S.

AU - Bernasconi, C.

PY - 1984

Y1 - 1984

N2 - Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.

AB - Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.

UR - http://www.scopus.com/inward/record.url?scp=0021739763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021739763&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 1339

EP - 1342

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 11

ER -